Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

By M. Caplin, Marianne Pavel,, J. Ćwikła, A. Phan, Markus Raderer, E. Sedláčková, Guillaume Cadiot, E. Wolin, Jaume Capdevila, Lucy Wall and 5 more. New England Journal of Medicine, 2014

1,674 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology

View Paper: https://www.semanticscholar.org/paper/3696455b604777b9ca8d05057081a467fb087a71

Citations in the corpus

• Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (2017, neutral): “Vomiting 52 (47) 8 (7) 11 (10) 1 (1) <0.”
• Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020, neutral): “SSAs can be recommended in patients with unknown disease status, stable or Lu, lutetium-177; IFN-a , interferon alpha; LAR, long-acting release; NET, neuroendocrine tumour; PRRT, peptide receptor radionuclide therapy; RFA, radiofrequency ablation; s.c., subcutaneous; SIRT, selective internal radioth”